Repeat TURBT Before RC Does Not Improve Bladder Cancer Outcomes
Study results suggest that tumor debulking does not benefit patients undergoing radical cystectomy.
Bladder Cancer News
BLADDER CANCER ADVISOR
Bladder Cancer News
Nab-Paclitaxel, Pembrolizumab Combo Active in Advanced Urothelial Cancer
Combination nab-paclitaxel and pembrolizumab demonstrated activity in platinum-refractory or cisplatin-ineligible advanced urothelial cancer.
Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer
Chemoresection with mitomycin reduces the number of required surgical procedures in recurrent nonmuscle invasive bladder cancer, a study suggests.
Enfortumab Vedotin Plus Pembrolizumab “Promising” for Untreated Advanced Urothelial Carcinoma
Patients with advanced urothelial carcinoma treated with first-line enfortumab vedotin plus pembrolizumab had a 93.3% disease control rate.
Local Docetaxel Therapy May Benefit Patients With High-Risk NMIBC
Of 19 patients with high-risk NMIBC treated with local docetaxel, 14 had prior BCG exposure.
MRI-Based Assessment May Eliminate Need for TURBT in Muscle-Invasive Bladder Cancer
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.
Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer
Adding tislelizumab to gemcitabine/cisplatin improved outcomes in patients with locally advanced or metastatic bladder cancer.
More Advanced Bladder Cancers Encountered After COVID-19 Pandemic
Investigators hypothesize that patients presented later to their health care providers during the first year of the pandemic.
Data Reveal Growing Burden of Metastatic Cancers in the US
The prevalence of metastatic cancers in the US has risen in recent years and will increase further by 2025, according to researchers.
Optimal Duration of Neoadjuvant Gemcitabine + Cisplatin for MIBC Probed
The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.
Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer
Gemcitabine plus docetaxel is safe and effective in BCG-naive high-risk non-muscle-invasive bladder cancer, according to researchers.
Previous Cannabis Use Linked to Lower Risk of Some Genitourinary Cancers
A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.
Opioid Use in Advanced Urothelial Carcinoma Quantified
Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma than among matched control individuals, a study showed.
Men Have Higher Risk of Cancer; Demographic and Lifestyle Factors Don’t Explain It
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
Recurrent NMIBC Effectively Treated With Salvage Valrubicin+Docetaxel
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Radiotherapy for Prostate Cancer May Increase Risk of Second Primary Cancer
Patients treated with radiotherapy had a greater risk of second primary cancer when compared with patients who underwent surgery or surveillance.
Sesen Bio Puts Development of Bladder Cancer Drug Vicineum on Pause
The biologics license application for Vicineum included preliminary findings from the phase 3 VISTA trial.
UTUC Adjuvant Chemotherapy Beneficial in Selected Cases
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
Data Support Trimodal Therapy for Muscle-Invasive Bladder Cancer
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Olaparib Does Not Improve Outcomes in Platinum-Ineligible Metastatic Urothelial Carcinoma
Adding olaparib to durvalumab did not improve progression-free or overall survival.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...